Print preview Close
Showing 36 results
Archival DescriptionTreatment start and treatment duration as determinants of treatment program health outcomes and cost-effectiveness
Treatment start and treatment duration as determinants of treatment program health outcomes and cost-effectiveness
Serono grant application for Multiple Sclerosis Health Care Costs in Nova Scotia: A Population-based Life-cycle Study
Serono grant application for Multiple Sclerosis Health Care Costs in Nova Scotia: A Population-based Life-cycle Study
Serono Canada grant application and report
Serono Canada grant application and report
Observed DALYs avoided and QALYs gained in ambulatory definite relapsing onset multiple sclerosis cohort exposed to first-generation disease-modifying therapies
Observed DALYs avoided and QALYs gained in ambulatory definite relapsing onset multiple sclerosis cohort exposed to first-generation disease-modifying therapies
National Multiple Sclerosis Society (NMSS) COSTRIMS study
National Multiple Sclerosis Society (NMSS) COSTRIMS study
Murray G. Brown fonds
Murray G. Brown fonds
Multiple Sclerosis PharmacoEconomic Evaluation Tool (MS PEET) version 2 users manual
Multiple Sclerosis PharmacoEconomic Evaluation Tool (MS PEET) version 2 users manual
Multiple sclerosis net benefits feasibility study
Multiple sclerosis net benefits feasibility study
Multiple Sclerosis Integrated Database (MSID) datasets
Multiple Sclerosis Integrated Database (MSID) datasets
Multiple sclerosis disease-modifying drug and health care costs in Nova Scotia, 1989 -2003 / Vern Hicks, Murray G. Brown, I.S. Sketris
Multiple sclerosis disease-modifying drug and health care costs in Nova Scotia, 1989 -2003 / Vern Hicks, Murray G. Brown, I.S. Sketris
MS cost-effectiveness study correspondence and meeting notes
MS cost-effectiveness study correspondence and meeting notes
Modelling health outcomes in relapsing-remitting-onset multiple sclerosis cohorts treated with disease-modifying drugs that delay disability progression
Modelling health outcomes in relapsing-remitting-onset multiple sclerosis cohorts treated with disease-modifying drugs that delay disability progression
Modelling disease progression & treatment effects in multiple sclerosis within a cost-effectiveness study / Murray G. Brown & Chris Skedgel
Modelling disease progression & treatment effects in multiple sclerosis within a cost-effectiveness study / Murray G. Brown & Chris Skedgel
Measuring the consequences of MS in Canada : economic effects
Measuring the consequences of MS in Canada : economic effects
Letter of intent to Health Canada on Assessing the Effectiveness of Marketed Pharmaceutical Products in the "Real World"
Letter of intent to Health Canada on Assessing the Effectiveness of Marketed Pharmaceutical Products in the "Real World"
Information sinkholes on the road to representative estimates of MS disability progression speed ....
Information sinkholes on the road to representative estimates of MS disability progression speed ....
How effective are new drugs in delaying disability progression in relapsing remitting onset multiple sclerosis? A subgroup analysis
How effective are new drugs in delaying disability progression in relapsing remitting onset multiple sclerosis? A subgroup analysis
First-generation disease-modifying therapy exposure effects on disability burden in ambulatory relapsing-onset MS : fixed effects regression model estimates from 1979-2010 Nova Scotia data
First-generation disease-modifying therapy exposure effects on disability burden in ambulatory relapsing-onset MS : fixed effects regression model estimates from 1979-2010 Nova Scotia data
Evaluation of health-related quality of life utility measures in patients with multiple sclerosis
Evaluation of health-related quality of life utility measures in patients with multiple sclerosis
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Email between Sarah Kirby and Murray Brown regarding modelling for research on drug efficacy in delaying disability progression in relapsing remitting onset MS
Email between Sarah Kirby and Murray Brown regarding modelling for research on drug efficacy in delaying disability progression in relapsing remitting onset MS
Effectiveness and cost-effectiveness of new multiple sclerosis drugs the "real world" : final report to Health Policy Research Program, Health Canada
Effectiveness and cost-effectiveness of new multiple sclerosis drugs the "real world" : final report to Health Policy Research Program, Health Canada
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world" : final report
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world" : final report
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world"
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world"
EDSS natural history atlas : multiple sclerosis disability progression in Nova Scotia, 1979-2004
EDSS natural history atlas : multiple sclerosis disability progression in Nova Scotia, 1979-2004
Disability progression in multiple sclerosis is faster than observed
Disability progression in multiple sclerosis is faster than observed
Dalhousie MS Research Group meeting minutes
Dalhousie MS Research Group meeting minutes
Cost-effectiveness of multiple sclerosis drugs in the "real world"
Cost-effectiveness of multiple sclerosis drugs in the "real world"
Cost-effectiveness of Interferon Beta-1B in slowing multiple sclerosis disability progression : first estimates
Cost-effectiveness of Interferon Beta-1B in slowing multiple sclerosis disability progression : first estimates
Correspondence and reports regarding Biogen / Axia Research
Correspondence and reports regarding Biogen / Axia Research
Conference schedule for MS research presentations
Conference schedule for MS research presentations
Clinical effectiveness of disease modifying treatment (DMT) that delays disability progression in relapsing/remitting-onset MS
Clinical effectiveness of disease modifying treatment (DMT) that delays disability progression in relapsing/remitting-onset MS
Benign multiple sclerosis : a 25-year retrospective analysis and redefinition
Benign multiple sclerosis : a 25-year retrospective analysis and redefinition
Abstract, poster, and presentations on MS research
Abstract, poster, and presentations on MS research
A therapeutic and economic assessment of Betaseron in multiple sclerosis
A therapeutic and economic assessment of Betaseron in multiple sclerosis